PUUSTELLI-GROUP
Puustelli has innovated a unique furniture system to eliminate moisture problems in bathroom fittings. The furniture frames feature a structure made of biocomposite by injection moulding. The biocomposite is a mixture of polypropylene and chemical pulp fibre, and is a water-resistant, non-toxic, ecological, modifiable and lasting material. This Finnish product innovation has been developed and is made 100% in Finland. The furniture system, which is suitable for kitchen furniture, has been in production in Puustelli Miinus kitchens since back in 2013. Puustelli was granted a European patent for its invention in 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005234/en/
Water-resistant material
Most bathroom fittings typically have a frame of MDF or particleboard, both of which have poor moisture resistance. The biocomposite frame in Puustelli bathroom fittings can fully withstand water and comes with a 30-year guarantee.
Low-emission concept
Formaldehyde is also present in the panel materials typically used in bathroom fittings. When emitted into the indoor air, formaldehyde is harmful to the health. Even when the panel structure is only slightly damaged, the impact of moisture multiplies the harmful effects. The Puustelli biocomposite frame has a formaldehyde content of exactly 0%. Not only that, the biocomposite is antistatic and does not attract dust.
Ecological solution
Once a frame made from conventional furniture board has absorbed moisture, it can no longer be repaired and must be disposed of and replaced. The Puustelli biocomposite frame on the other hand is a fully reusable and recyclable material. Since it is recyclable, any waste raw material originating in the manufacturing process of the Puustelli biocomposite frame can be efficiently reused.
Puustelli bioframe can be modified
Unlike traditional frame materials, the Puustelli bioframe doesn’t tire of modification or being moved. The frame has precise dimensional accuracy and fittings and materials that affect its appearance can be switched around numerous times if required without the screw fastenings becoming fatigued. The furniture is available for large and small spaces alike. The frames can be finished in various ways depending on the range. Puustelli has also developed from the composite for the frame, a design end panel with a restrained pattern suitable for different styles. Small locators have also been made in the panel in conjunction with injection moulding to make it easy to screw the end panel accurately into the ready-made holes in the frame. The bioframes of the washbasin cupboards have been designed for careful use of space. Plumbing has also been taken into account and if necessary can easily be accessed later. Base cabinets come at a height of 613 mm and widths vary between 200 mm and 1200 mm depending on the model. Since the depth is just 370 mm, they can fit into small spaces.
“The bathroom product development process has been long and at times challenging, but the outcome was well worth all the work. Following our kitchen furniture, a similar bathroom fitting innovation was already anticipated and is now in production,” says Jussi Aine, CEO, Puustelli Group Oy.
Puustelli Group Oy is a Finnish family enterprise and part of the century-old Harjavalta Group, which also includes Kastelli Group Oy and Lapti Group Oy. The Group had a turnover of €491 million in 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom